{'fraction_non_alphanumeric': 0.023465703971119134, 'fraction_numerical': 0.009025270758122744, 'mean_word_length': 5.306818181818182, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Cost-effectiveness of beta-blocker treatment in heart failure.

There is a growing economic burden from the treatment of heart failure that accounts for more than 5% of total health care expenditures. Hospitalization contributes between 60% and 75% of this total expense. The addition of beta-blockers to conventional heart failure therapy results in a significant reduction in hospitalization. As a consequence, beta-blocker therapy in heart failure is very cost-effective and compares favorably to that of other generally accepted medical interventions